- Home
- ASGN vs ZLAB Comparison
ASGN vs ZLAB Comparison
Compare ASGN & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASGN | ZLAB |
|---|---|---|
| Founded | 1985 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1992 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ASGN | ZLAB |
|---|---|---|
| Price | $50.49 | $18.48 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $46.60 | ★ $53.52 |
| AVG Volume (30 Days) | 530.2K | ★ 855.2K |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.96 | N/A |
| Revenue | ★ $3,985,300,000.00 | $441,629,000.00 |
| Revenue This Year | N/A | $26.16 |
| Revenue Next Year | $0.54 | $30.62 |
| P/E Ratio | $16.37 | ★ N/A |
| Revenue Growth | N/A | ★ 24.14 |
| 52 Week Low | $39.25 | $16.82 |
| 52 Week High | $95.29 | $44.34 |
Technical Indicators
Market Signals| Indicator | ASGN | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 64.20 | 47.52 |
| Support Level | $45.92 | $17.18 |
| Resistance Level | $48.59 | $19.32 |
| Average True Range (ATR) | 1.26 | 0.59 |
| MACD | -0.07 | 0.33 |
| Stochastic Oscillator | 92.35 | 63.30 |
Price Performance
Historical ComparisonAbout ASGN ASGN Incorporated
ASGN Inc is a provider of information technology (IT) services and professional solutions, including technology, creative, and digital, across the commercial and government sectors. It operates through two segments, Commercial and Federal Government. The Commercial Segment, which generates the majority of the revenue, provides consulting, creative digital marketing, and permanent placement services to Fortune 1000 clients and mid-market companies. The Federal Government Segment provides mission-critical solutions to the Department of Defense, intelligence agencies, and civilian agencies.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.